Product image of Micafungin Hikma (Micafungin) supplied by GNH India

Micafungin Hikma

Active Ingredient:
Micafungin
Origin:
EU

Micafungin Hikma (Micafungin)

Micafungin, the active ingredient in Micafungin Hikma, is an echinocandin presented as an intravenous formulation for intravenous use. It treats invasive candidiasis and related fungal infections in immunocompromised patients.

GNH India supplies Micafungin Hikma as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals worldwide.

Manufacturer / TM Owner

Hikma Farmacêutica (Portugal), S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Micafungin is an echinocandin antifungal used to manage serious Candida infections.

  • Invasive candidiasis: eradicates bloodstream and deep‑tissue Candida infections.
  • Esophageal candidiasis: resolves mucosal Candida overgrowth in the esophagus.
  • Prophylaxis of Candida infections in hematopoietic stem cell transplantation: prevents invasive candidiasis in transplant recipients.
  • Candida peritonitis: treats intra‑abdominal Candida infections.
  • Candida bloodstream infections: clears fungemia caused by Candida species.

How It Works

  • Micafungin inhibits the enzyme β‑(1,3)‑D‑glucan synthase, which is essential for synthesizing β‑(1,3)‑D‑glucan, a critical component of the fungal cell wall. By disrupting cell‑wall formation, the drug leads to osmotic instability and fungal cell death, while having minimal effect on human cells that lack this pathway.

Side Effects

Micafungin may cause a range of adverse reactions, from mild to severe.

Common Side Effects

  • Fever: transient elevation of body temperature.
  • Nausea: mild to moderate upset stomach.
  • Headache: occasional mild headache.
  • Infusion‑related reactions: flushing, chills, or mild hypotension during administration.
  • Elevated liver enzymes: transient increase in ALT/AST.
  • Rash: mild skin erythema.

Serious or Rare Side Effects

  • Severe hypersensitivity: anaphylaxis or angioedema.
  • Hepatotoxicity: significant liver injury with jaundice.
  • Severe hypotension: marked drop in blood pressure requiring intervention.
  • Acute renal failure: sudden loss of kidney function.
  • Stevens‑Johnson syndrome: rare severe skin reaction.
  • Cytopenias: notable reductions in blood cell counts.

Precautions & Warnings

Before using Micafungin, clinicians should consider several safety measures.

  • Liver function monitoring: assess baseline and periodic ALT/AST levels.
  • Renal function assessment: evaluate creatinine clearance, especially in patients with pre‑existing kidney disease.
  • Hypersensitivity screening: avoid in patients with known allergy to echinocandins.
  • Cardiovascular caution: monitor blood pressure during infusion in patients with heart failure.
  • Drug interaction review: check concomitant medications that affect hepatic metabolism.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Micafungin can interact with several agents; awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid)

  • Cyclosporine: increased cyclosporine exposure may cause nephrotoxicity.
  • Tacrolimus: elevated tacrolimus levels can lead to toxicity.
  • Sirolimus: risk of heightened immunosuppression.

Moderate Interactions (Monitor Closely)

  • Warfarin: potential alteration of INR; monitor coagulation.
  • Oral contraceptives: reduced efficacy possible; advise alternative contraception.
  • Rifampin: may decrease micafungin concentrations.
  • Carbamazepine: may lower micafungin exposure.
  • Fluconazole: additive antifungal effect; monitor for toxicity.

Frequently Asked Questions

Micafungin Hikma is indicated for invasive candidiasis, esophageal candidiasis, prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation, Candida peritonitis, and Candida bloodstream infections. It is used in patients at high risk for serious fungal disease.

Micafungin inhibits the fungal enzyme β‑(1,3)‑D‑glucan synthase, which is essential for producing β‑(1,3)‑D‑glucan, a key structural component of the fungal cell wall. Disruption of cell‑wall synthesis leads to osmotic instability and cell death, while human cells are unaffected because they lack this pathway.

The dosing regimen for Micafungin Hikma is determined by the prescribing clinician based on the specific indication, patient weight, renal and hepatic function, and other clinical factors. Healthcare providers set the appropriate intravenous dose and infusion duration.

The safety of Micafungin Hikma in pregnancy and lactation has not been definitively established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by the treating physician.

To order Micafungin Hikma, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed), and necessary import documentation.

Micafungin belongs to the echinocandin class, which targets the fungal cell wall, whereas azoles (e.g., fluconazole) inhibit ergosterol synthesis and polyenes (e.g., amphotericin B) bind membrane sterols. Echinocandins like micafungin are often preferred for invasive Candida infections due to their fungicidal activity and lower nephrotoxicity compared with polyenes.

Micafungin Hikma should be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect them from light, and do not freeze or shake the product. Maintaining the cold chain preserves stability and potency.

Micafungin Hikma is given by intravenous infusion. The infusion is typically administered over 30‑60 minutes, depending on the prescribed dose and clinical protocol. Administration should be performed by qualified healthcare personnel in a setting equipped for IV therapy.

Serious risks include severe hypersensitivity reactions such as anaphylaxis, significant liver injury indicated by marked elevations in transaminases, acute renal failure, and rare severe skin reactions like Stevens‑Johnson syndrome. Patients should be monitored closely for any signs of these events.

Micafungin Hikma should be avoided in individuals with a known hypersensitivity to micafungin or any component of the formulation. Caution is also advised for patients with severe hepatic impairment, uncontrolled heart failure, or those receiving interacting immunosuppressants without appropriate monitoring.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Micafungin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT